Label-free Array System Market Share, Size, Trends, Industry Analysis Report, By Type (Surface Plasmon Resonance, Bio-layer Interferometry, Cellular Dielectric Spectroscopy, Others); By Application; By End-user; By Region; Segment Forecast, 2023 - 2032
- Published Date:Jun-2023
- Pages: 115
- Format: PDF
- Report ID: PM3344
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global label-free array system market was valued at USD 453.94 million in 2022 and is anticipated to grow at a CAGR of 7.3% during the forecast period. The increasing demand for point-of-care testing is driving the growth of the label-free array system market in the healthcare industry. Label-free array systems can provide rapid and accurate results, enabling early detection and treatment of diseases. This is particularly important in point-of-care testing, where time is of the essence. They can also detect biomolecular interactions with high sensitivity and specificity, making them ideal for point-of-care testing. They can detect small molecules and low concentrations of biomarkers, which is critical in disease diagnosis and monitoring.
To Understand More About this Research: Request a Free Sample Report
For instance, in a paper published by researchers at University of Alberta, Canada developed a new impedimetric immune-sensor for PoC detection of COVID-19 antibodies. Using the SARS-CoV-2 spike protein as the probe, the device to specifically detect the COVID patients antibodies in human samples. As a result, the sensor exhibits great sensitivity and specificity in distinguishing COVID-19-positive from COVID-19-negative human blood samples.
The pharmaceutical industry is growing rapidly, and label-free arrays are being increasingly adopted by pharmaceutical companies for drug discovery. This growth is expected to continue, particularly in emerging markets, which will further boost demand for label-free arrays. Label-free array systems play an important role in identifying biomarkers and studying protein interactions, making them essential for the development of personalized medicine due to which many companies are greatly investing in research and development of label-free array system which is driving the market growth.
For Specific Research Requirements, Request for a Customized Report
Industry Dynamics
Growth Driver
Increasing awareness about the benefits of label-free array systems, such as their high sensitivity and specificity, their cost effectiveness is driving the growth of the label-free array system market. Researchers and clinicians are becoming more aware of the advantages of label-free array systems and are adopting them in their work. Label-free array systems can provide rapid and accurate diagnostics, enabling early detection and treatment of diseases. Label-free array systems are used for high-throughput screening of compounds, which is a significant advantage in the pharmaceutical industry. This technology allows for the rapid screening of thousands of compounds in a short period, enabling researchers to identify potential drug candidates quickly which is augmenting market growth.
Report Segmentation
The market is segmented based on type, application, end-use and region.
|
By Type |
By Application |
By End-User |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Surface Plasmon Resonance segment is expected to grow at a high CAGR during the forecast period
The Surface Plasmon Resonance (SPR) technology allows for the real-time, highly sensitive, and label-free measurement of biomolecular interactions, which is spurring industry expansion. For high-throughput screening of chemicals, SPR-based label-free array devices are being employed more often in drug discovery and development. This technique gives the pharmaceutical sector a considerable edge by enabling the quick screening of thousands of compounds in a short amount of time.
This segment is also expected to grow at a significant rate during the forecast period. In addition to being employed for a variety of purposes including drug discovery, the development of biosensors, and the study of molecular interactions, SPR technology is having a substantial influence on food analysis, pharmaceutical discovery, and fundamental research. The market is anticipated to increase in the next years as a result of this wide range of applications.
For instance, in February 2023, at the SLAS, Carterra unveiled the LSAXT, their newest High Throughput-Surface Plasmon Resonance instrument. Carterra's wildly popular LSA platform gains enhanced sensitivity with the LSAXT, allowing new throughput-level applications for drug discovery and development. Additionally, it provides 100 times the data in 10% the time to respond and only utilizes 1% of the sample used by existing label-free systems.
Protein Interface Analysis segment is anticipated to exhibit high CAGR
Protein interface analysis segment is anticipated to grow at a high CAGR during the forecast period. Protein interface analysis has become more precise and efficient because to the development of new label-free array technologies such as microfluidic-based assays. These developments have made it possible to characterize protein complexes and identify novel protein-protein interactions, both of which are critical steps in the creation of protein therapies. Additionally, label-free arrays provide a cost-effective and efficient way to study protein-protein interactions, which is essential for the development of protein therapeutics. These factors are contributing to the market growth.
Drug Discovery segment accounted for the largest market share in 2022. Label-free array systems easily solve a number of complex issues, such as the screening of otherwise unsolvable targets, the detection of small molecules that are difficult to label, and the performance of assays on live cells with the ability to gather information from both single cells and large cell populations in the drug discovery lab which is responsible for market growth. In February 2023, Agilent Technologies announced the integration of the BioTek Bio-Spa 8 Automated for the real time cell analysis. This combination makes it possible to automate workflows at a higher level, enabling the creation of innovative functionality for label-free high-throughput potency tests for the immuno-oncology industry for the vaccine market.
North America region dominated the market in 2022
The healthcare system in North America is highly developed, and both public and commercial institutions are making significant investments in life sciences research and development, including drug discovery. As a result, funding for label-free array system research and development has significantly increased which is augmenting market expansion. The region has a high frequency of chronic illnesses including cancer, diabetes, and cardiovascular conditions as well as a strong demand for personalized medication. Label-free array systems are being increasingly used in the diagnosis and treatment of these diseases, which is driving demand for these systems in the region.
Asia-Pacific region is anticipated to expand throughout the projection period at a high CAGR. Label-free array systems are a crucial tool for identifying biomarkers and researching protein interactions, which is crucial for the advancement of personalized treatment. Furthermore, biotechnology and pharmaceutical industries are growing rapidly in this region, particularly in China, India, and Japan. Label-free array systems are being increasingly adopted by these industries for protein interaction analysis, which is driving demand for these systems in the region.
Competitive Insight
Some of the major players operating in the global market include among others Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, Corning Incorporated, Merck KGaA, Danaher Corporation, Attana AB, Bio-Rad Laboratories, Roche AG, GWC Technologies, BiOptix inc., Becton Dickinson & Sartorius.
Recent Developments
- In March 2023, Charles River Laboratories purchased SAMDI Tech. The acquisition follows more than a decade of expansion made possible by SAMDI Tech's occupancy of the University Technology Park (UTP) incubator at Illinois Institute of Technology.
- In May 2022, Sartorius unveiled the new Octet SF3, the company's 1st Surface Plasmon Resonance solution. Due to the system's low base-line noise & drift, large injection volumes, & novel injection techniques, users may generate better kinetics & the affinity data short time period.
Label-free Array System Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 486.17 million |
|
Revenue forecast in 2032 |
USD 920.47 million |
|
CAGR |
7.3% from 2023– 2032 |
|
Base year |
2022 |
|
Historical data |
2019– 2021 |
|
Forecast period |
2023- 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments covered |
By Type, By Application, By End-user, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Corning Incorporated, Merck KGaA, Danaher Corporation, Attana AB, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GWC Technologies, BiOptix inc., Becton Dickinson and Company and Sartorius AG |
FAQ's
The label-free array system market report covering key segments are type, application, end-use and region.
Label-Free Array System Market Size Worth $920.47 Million By 2032.
The global label-free array system market anticipated to grow at a CAGR of 7.3% during the forecast period.
North America is leading the global market.
key driving factors in label-free array system market are increasing awareness about the benefits of label-free array systems.
